Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Antiretroviral penetration across three preclinical animal models and humans in eight putative HIV viral reservoirs.

Devanathan AS, Pirone JR, Akkina R, Remling-Mulder L, Luciw P, Adamson L, Garcia JV, Kovarova M, White NR, Schauer AP, Blake K, Sykes C, Burgunder EM, Srinivas N, Rosen EP, Kashuba ADM.

Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01639-19. doi: 10.1128/AAC.01639-19. [Epub ahead of print]

PMID:
31611355
2.

Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.

Burgunder E, Fallon JK, White N, Schauer AP, Sykes C, Remling-Mulder L, Kovarova M, Adamson L, Luciw P, Garcia JV, Akkina R, Smith PC, Kashuba ADM.

J Pharmacol Exp Ther. 2019 Sep;370(3):360-368. doi: 10.1124/jpet.119.259150. Epub 2019 Jun 24.

PMID:
31235531
3.

Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.

Greene SA, Chen J, Prince HMA, Sykes C, Schauer AP, Blake K, Nelson JAE, Gay CL, Cohen MS, Dumond JB.

Clin Pharmacol Ther. 2019 Oct;106(4):821-830. doi: 10.1002/cpt.1464. Epub 2019 May 31.

PMID:
31002391
4.

Decreased tenofovir diphosphate concentrations in a transgender female cohort: Implications for HIV pre-exposure prophylaxis (PrEP).

Cottrell ML, Prince HMA, Schauer AP, Sykes C, Maffuid K, Poliseno A, Chun TW, Huiting E, Stanczyk FZ, Peery AF, Dellon ES, Adams JL, Gay C, Kashuba ADM.

Clin Infect Dis. 2019 Apr 9. pii: ciz290. doi: 10.1093/cid/ciz290. [Epub ahead of print]

PMID:
30963179
5.

Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.

Srinivas N, Joseph SB, Robertson K, Kincer LP, Menezes P, Adamson L, Schauer AP, Blake KH, White N, Sykes C, Luciw P, Eron JJ, Forrest A, Price RW, Spudich S, Swanstrom R, Kashuba ADM.

Clin Transl Sci. 2019 May;12(3):302-311. doi: 10.1111/cts.12620. Epub 2019 Feb 27.

6.

Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.

Dumond JB, Greene SA, Prince HMA, Chen J, Maas BM, Sykes C, Schauer AP, Blake KH, Nelson JAE, Gay CL, Kashuba ADM, Cohen MS.

Antivir Ther. 2019;24(1):45-50. doi: 10.3851/IMP3277.

PMID:
30375984
7.

Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species.

Srinivas N, Rosen EP, Gilliland WM Jr, Kovarova M, Remling-Mulder L, De La Cruz G, White N, Adamson L, Schauer AP, Sykes C, Luciw P, Garcia JV, Akkina R, Kashuba ADM.

Xenobiotica. 2019 Oct;49(10):1192-1201. doi: 10.1080/00498254.2018.1539278. Epub 2018 Dec 17.

PMID:
30346892
8.

Development and validation of an LC-MS/MS assay for the quantification of dolutegravir extracted from human hair.

Sykes C, Blake K, White N, Schauer AP, Guzman BB, Cottrell ML, Tamraz B, Kashuba ADM.

Anal Bioanal Chem. 2018 Nov;410(29):7773-7781. doi: 10.1007/s00216-018-1394-y. Epub 2018 Oct 2.

9.

A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.

Garrett KL, Chen J, Maas BM, Cottrell ML, Prince HA, Sykes C, Schauer AP, White N, Dumond JB.

J Pharmacol Exp Ther. 2018 Nov;367(2):245-251. doi: 10.1124/jpet.118.251009. Epub 2018 Aug 27.

10.

Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.

Schauer AP, Sykes C, Cottrell ML, Prince H, Kashuba ADM.

J Pharm Biomed Anal. 2018 Feb 5;149:40-45. doi: 10.1016/j.jpba.2017.10.030. Epub 2017 Oct 31.

Supplemental Content

Loading ...
Support Center